Costs keep older rural cancer survivors away from health services
Reducing disparities between urban and rural health care may involve addressing out-of-pocket costs, particularly for older persons who have survived cancer, researchers found.
All articles by Delicia Honen Yard
One hour of walking per day may reduce breast cancer risk
Researchers have uncovered a decreased risk of breast cancer among women who walk 7 or more hours per week compared with women who walk for 3 hours or less per week.
HARM score measures colorectal surgery outcomes
A new tool known as the HARM score may provide a low-cost solution for comparative quality assessment in colorectal surgery for patients with cancer and other conditions, say the developers of the formula.
Ramucirumab prolongs survival in advanced gastric cancer
An investigational drug improved median survival while reducing risk of disease progression or death in persons with metastatic gastric cancer participating in the phase III REGARD trial.
Ipecac component enhances cisplatin in bladder cancer
The use of emetine dihydrochloride, an active ingredient in ipecac syrup, alone or with cisplatin therapy inhibited proliferation of bladder tumor cells in a recent study.
Some lymph nodes can be spared after partial mastectomy
Removal of all axillary lymph nodes may be unnecessary in women undergoing breast-conserving therapy (partial mastectomy followed by whole-breast radiation), researchers have found.
Abiraterone delayed pain in men with metastatic prostate cancer
Men with mCRPC who had not undergone previous chemotherapy reported delayed pain progression and prolonged health-related quality of life with abiraterone acetate plus prednisone, compared with prednisone alone.
Young women overestimate cancer risk in second breast
Many women with breast cancer overestimate their risk for developing the disease in the unaffected breast and undergo contralateral prophylactic mastectomy (CPM) despite knowing that this procedure does not clearly improve survival.
Local recurrence less likely after radiotherapy for DCIS
In women with ductal carcinoma in situ (DCIS), breast-conserving treatment combined with radiotherapy reduces the risk for local recurrence (LR), a recent study indicates.
A roundup of FDA oncology news from September 2013
The FDA approved Perjeta (pertuzumab) for the neoadjuvant treatment of breast cancer, first generic version of Xeloda (capecitabine) has gained FDA approval, and other FDA actions.
